Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis

References

• MunroRHampsonRMcEntegartAThomsonEAMadhokRCapellHImproved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective studyAnn Rheum Dis199857288939613337
   PubMed Web of Science ®Google Scholar
• Goekoop-RuitermanYPde Vries-BouwstraJKAllaartCFClinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trialArthritis Rheum200552113381339016258899
   PubMed Web of Science ®Google Scholar
• van der HeideAJacobsJWBijlsmaJWThe effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trialAnn Intern Med199612486997078633829
   PubMed Web of Science ®Google Scholar
• NellVPMacholdKPEberlGStammTAUffmannMSmolenJSBenefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritisRheumatology (Oxford)200443790691415113999
   PubMed Web of Science ®Google Scholar
• SmolenJSLandeweRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnn Rheum Dis201473349250924161836
   PubMed Web of Science ®Google Scholar
• NamJLRamiroSGaujoux-VialaCEfficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritisAnn Rheum Dis201473351652824399231
   PubMed Web of Science ®Google Scholar
• SayeghMHTurkaLAThe role of T-cell costimulatory activation pathways in transplant rejectionN Engl J Med199833825181318219632449
   PubMed Web of Science ®Google Scholar
• FoyTMAruffoABajorathJBuhlmannJENoelleRJImmune regulation by CD40 and its ligand GP39Annu Rev Immunol1996145916178717526
   PubMed Web of Science ®Google Scholar
• LenschowDJWalunasTLBluestoneJACD28/B7 system of T-cell costimulationAnnu Rev Immunol1996142332588717514
   PubMed Web of Science ®Google Scholar
• QuattrocchiEDallmanMJFeldmannMAdenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritisArthritis Rheum20004381688169710943858
   PubMed Web of Science ®Google Scholar
• LarsenCPElwoodETAlexanderDZLong-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathwaysNature199638165814344388632801
   PubMed Web of Science ®Google Scholar
• CorboMValenciaXRaymondRSummerillRAgrawalSTownsendRSubcutaneous administration of abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenicityAnn Rheum Dis200968S574
   Google Scholar
• SchiffMPritchardCHuffstutterJEThe 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trialAnn Rheum Dis200968111708171419074911
   PubMed Web of Science ®Google Scholar
• GenoveseMCBeckerJCSchiffMAbatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibitionN Engl J Med2005353111114112316162882
   PubMed Web of Science ®Google Scholar
• WesthovensRKremerJMMorelandLWSafety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended Phase IIB studyJ Rheumatol200936473674219273451
   PubMed Web of Science ®Google Scholar
• KremerJMRussellASEmeryPLong-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trialAnn Rheum Dis201170101826183021893583
   PubMed Web of Science ®Google Scholar
• KremerJMGenantHKMorelandLWEffects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trialAnn Intern Med20061441286587616785475
   PubMed Web of Science ®Google Scholar
• WesthovensRRoblesMXimenesACClinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factorsAnn Rheum Dis200968121870187719124524
   PubMed Web of Science ®Google Scholar
• GenoveseMCCovarrubiasALeonGSubcutaneous abatacept versus intravenous abatacept: a Phase IIIb noninferiority study in patients with an inadequate response to methotrexateArthritis Rheum201163102854286421618201
   PubMed Web of Science ®Google Scholar
• NashPNayiagerSGenoveseMCImmunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a Phase III, international, multicenter, parallel-arm, open-label studyArthritis Care Res (Hoboken)201365571872823097311
   PubMed Web of Science ®Google Scholar
• KaineJGladsteinGStrusbergIEvaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (Phase Iiib ALLOW study)Ann Rheum Dis2012711384421917824
   PubMed Web of Science ®Google Scholar
• KeystoneECKremerJMRussellAAbatacept in subjects who switch from intravenous to subcutaneous therapy: results from the Phase IIIb ATTUNE studyAnn Rheum Dis201271685786122302417
   PubMed Web of Science ®Google Scholar
• WeinblattMESchiffMValenteRHead-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a Phase IIIb, multinational, prospective, randomized studyArthritis Rheum2013651283823169319
   PubMed Web of Science ®Google Scholar
• SchiffMWeinblattMEValenteRHead-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trialAnn Rheum Dis2014731869423962455
   PubMed Web of Science ®Google Scholar
• van der HeijdeDHow to read radiographs according to the Sharp/van der Heijde methodJ Rheumatol200027126126310648051
   PubMed Web of Science ®Google Scholar
• GenoveseMPacheco-TenaCCovarrubiasALeonGMyslerEKeisermanMSubcutaneous abatacept: long-term data from the ACQUIRE trialArthritis Rheum201264Suppl 10S201
   Google Scholar
• SchellekensHFactors influencing the immunogenicity of therapeutic proteinsNephrol Dial Transplant200520Suppl 6vi3vi915958824
   PubMed Web of Science ®Google Scholar
• HaggertyHGAbbottMAReillyTPEvaluation of immunogenicity of the T-cell costimulation modulator abatacept in patients treated for rheumatoid arthritisJ Rheumatol200734122365237318050376
   PubMed Web of Science ®Google Scholar
• DoreRKMathewsSSchechtmanJThe immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritisClin Exp Rheumatol2007251404617417989
   PubMed Web of Science ®Google Scholar
• BarteldsGMWijbrandtsCANurmohamedMTClinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnn Rheum Dis200766792192617301106
   PubMed Web of Science ®Google Scholar
• AltenRKaineJKeystoneESafety profile of subcutaneous abatacept focusing on clinically relevant events in patients with rheumatoid arthritis (RA) and up to 4.5 years of exposureArthritis Rheum201163S150
   Web of Science ®Google Scholar
• AltenRKaineJKeystoneENashPDelaetIQiKSafety of subcutaneous abatacept in patients with rheumatoid arthritis (RA): integrated analysis of five clinical trials up to 4.5 yearsAnn Rheum Dis201170Suppl 3617
   Google Scholar
• WilliamsELEdwardsCJPatient preferences in choosing anti-TNF therapies-R1Rheumatology (Oxford)200645121575157617085468
   PubMed Web of Science ®Google Scholar